ICAD INC (ICAD) [Rocket]

Date Filed	Type	Description
04/05/2021	GN	iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition
03/15/2021	GN	iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography
03/08/2021	GN	New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting
03/03/2021	GN	iCAD to Participate in the Cowen 41st Annual Health Care Conference
03/03/2021	GN	iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock
02/18/2021	GN	iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24
01/19/2021	GN	iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference
01/06/2021	GN	iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
12/29/2020	GN	iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
12/10/2020	GN	Solis Mammography Adopts iCAD's ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
12/03/2020	GN	iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution
11/30/2020	GN	iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020
11/25/2020	GN	iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress
11/24/2020	GN	iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales
10/23/2020	GN	New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
10/20/2020	GN	iCAD Signs Distribution Agreement with Change Healthcare
09/20/2020	GN	iCAD Responds to CMS' Finalized Radiation Oncology Alternative Payment Model
09/18/2020	GN	iCAD's IORT Excluded from CMS's Radiation Oncology Alternative Payment Model
08/27/2020	GN	iCAD to Present at the LD Micro 500 Virtual Conference
08/10/2020	GN	iCAD to Participate in the Guggenheim MedTech Disruptors Summit
08/04/2020	GN	iCAD Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020
07/15/2020	GN	ProFound AI™ Risk Receives CE Mark in Europe
06/29/2020	GN	iCAD Added to Russell 2000® Index
04/23/2020	GN	iCAD Announces Pricing of $12.5 Million Registered Direct Offering
04/13/2020	GN	iCAD Partners with the TME Breast Care Network to Host Virtual Event: Breast Care Roundtable in the Age of COVID-19
02/27/2020	GN	iCAD Reports Fourth Quarter and Full-Year 2019 Financial Results